Interpretation of the updates of the Chinese guidelines for the diagnosis and treatment of primary liver cancer (CNLC-2024 Edition)

被引：0
作者：
Su, Hao [1 ]
Wei, Yongguang [1 ,2 ,3 ]
Liao, Xiwen [1 ]
Zhu, Guangzhi [1 ]
Peng, Minhao [1 ]
Fan, Fang [4 ]
Peng, Tao [1 ,2 ,3 ]
机构：
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Nanning 530021, Guangxi, Peoples R China
[2] Guangxi Key Lab Enhanced Recovery Surg Gastrointes, Nanning 530021, Guangxi, Peoples R China
[3] Guangxi Med Univ, Key Lab High Incidence Tumor Prevent & Treatment, Minist Educ, Nanning 530021, Guangxi, Peoples R China
[4] Guangxi Med Univ, Tumor Hosp, Dept Continued Educ, Nanning 530021, Guangxi, Peoples R China
来源：
HEPATOMA RESEARCH | 2024年 / 10卷
基金：
中国国家自然科学基金;
关键词：
Primary liver cancer; hepatocellular carcinoma; guidelines; update; interpretation; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; UNRESECTABLE HEPATOCELLULAR-CARCINOMA; PORTAL-VEIN; OPEN-LABEL; 1ST-LINE TREATMENT; SORAFENIB; THERAPY; MULTICENTER; PLUS; EMBOLIZATION;
D O I：
10.20517/2394-5079.2024.70
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Additional randomized controlled studies and high-level evidence for the diagnosis and management of liver cancer patients have been published since the release of Diagnosis and Treatment of Primary Liver Cancer Guidelines (CNLC-2022 edition). The 2024 version algorithm was updated accordingly by the national expert committee for the standardization and homogenization of liver cancer diagnosis and treatment in China. In this review, with reference to the guidelines of the 2022 version, we interpreted the main update points of the 2024 version to facilitate the nationwide dissemination and implementation of the guidelines.
引用
收藏
页数：12
相关论文
共 102 条
[91]   TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study [J].
Yuan, Yichuan ;
He, Wei ;
Yang, Zhiwen ;
Qiu, Jiliang ;
Huang, Zhenkun ;
Shi, Yunxing ;
Lin, Zhu ;
Zheng, Yun ;
Chen, Minshan ;
Lau, Wan Yee ;
Li, Binkui ;
Yuan, Yunfei .
INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (05) :1222-1230
[92]   Recent advances in systemic therapy for hepatocellular carcinoma [J].
Zhang, Huajun ;
Zhang, Wuyang ;
Jiang, Longying ;
Chen, Yongheng .
BIOMARKER RESEARCH, 2022, 10 (01)
[93]   An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study [J].
Zhang, Xiu-Ping ;
Gao, Yu-Zhen ;
Chen, Zhen-Hua ;
Chen, Min-Shan ;
Li, Le-Qun ;
Wen, Tian-Fu ;
Xu, Li ;
Wang, Kang ;
Choi, Zong-Tao ;
Guo, Wei-Xing ;
Shi, Jie ;
Xie, Dong ;
Wu, Meng-Chao ;
Lau, Wan Yee ;
Cheng, Shu-Qun .
HEPATOLOGY, 2019, 69 (05) :2076-2090
[94]   Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma [J].
Zhang, Yao Jun ;
Chen, Min Shan ;
Chen, Yong ;
Lau, Wan Yee ;
Peng, Zhenwei .
JAMA NETWORK OPEN, 2021, 4 (09) :E2126992
[95]   Response Evaluation Using Contrast-Enhanced Ultrasound for Unresectable Advanced Hepatocellular Carcinoma Treated With Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy [J].
Zhao, Chong-Ke ;
Guan, Xin ;
Pu, Yin-Ying ;
Zhou, Bo-Yang ;
Wang, Li-Fan ;
Sun, Yi-Kang ;
Yin, Hao-Hao ;
Xia, Han-Sheng ;
Wang, Xi ;
Han, Hong ;
Xu, Hui-Xiong .
ULTRASOUND IN MEDICINE AND BIOLOGY, 2024, 50 (01) :142-149
[96]   Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoembolization [J].
Zhong, Bin-Yan ;
Jiang, Jian-Qiang ;
Sun, Jun-Hui ;
Huang, Jin-Tao ;
Wang, Wei-Dong ;
Wang, Qi ;
Ding, Wen-Bin ;
Zhu, Xiao-Li ;
Ni, Cai-Fang .
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2023, 11 (06) :1321-1328
[97]   Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma [J].
Zhong, Liting ;
Wu, Dehua ;
Peng, Weiwei ;
Sheng, Hailong ;
Xiao, Yazhi ;
Zhang, Xuebing ;
Wang, Yuli .
FRONTIERS IN ONCOLOGY, 2021, 11
[98]   Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) [J].
Zhou, Jian ;
Sun, Huichuan ;
Wang, Zheng ;
Cong, Wenming ;
Zeng, Mengsu ;
Zhou, Weiping ;
Bie, Ping ;
Liu, Lianxin ;
Wen, Tianfu ;
Kuang, Ming ;
Han, Guohong ;
Yan, ZhiPing ;
Wang, Maoqiang ;
Liu, Ruibao ;
Lu, Ligong ;
Ren, Zhenggang ;
Zeng, ZhaoChong ;
Liang, Ping ;
Liang, Changhong ;
Chen, Min ;
Yan, Fuhua ;
Wang, Wenping ;
Hou, Jinlin ;
Ji, Yuan ;
Yun, Jingping ;
Bai, Xueli ;
Cai, Dingfang ;
Chen, Weixia ;
Chen, Yongjun ;
Cheng, Wenwu ;
Cheng, Shuqun ;
Dai, Chaoliu ;
Guo, Wenzhi ;
Guo, Yabing ;
Hua, Baojin ;
Huang, Xiaowu ;
Jia, Weidong ;
Li, Qiu ;
Li, Tao ;
Li, Xun ;
Li, Yaming ;
Li, Yexiong ;
Liang, Jun ;
Ling, Changquan ;
Liu, Tianshu ;
Liu, Xiufeng ;
Lu, Shichun ;
Lv, Guoyue ;
Mao, Yilei ;
Meng, Zhiqiang .
LIVER CANCER, 2023, 12 (05) :405-444
[99]   Plasma MicroRNA Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma [J].
Zhou, Jian ;
Yu, Lei ;
Gao, Xue ;
Hu, Jie ;
Wang, Jiping ;
Dai, Zhi ;
Wang, Jie-Fei ;
Zhang, Zhiyong ;
Lu, Shaohua ;
Huang, Xiaowu ;
Wang, Zheng ;
Qiu, Shuangjian ;
Wang, Xiaoying ;
Yang, Guohuan ;
Sun, Huichuan ;
Tang, Zhaoyou ;
Wu, Ying ;
Zhu, Hongguang ;
Fan, Jia .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (36) :4781-4788
[100]   Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Zhu, Andrew X. ;
Kang, Yoon-Koo ;
Yen, Chia-Jui ;
Finn, Richard S. ;
Galle, Peter R. ;
Llovet, Josep M. ;
Assenat, Eric ;
Brandi, Giovanni ;
Pracht, Marc ;
Lim, Ho Yeong ;
Rau, Kun-Ming ;
Motomura, Kenta ;
Ohno, Izumi ;
Merle, Philippe ;
Daniele, Bruno ;
Shin, Dong Bok ;
Gerken, Guido ;
Borg, Christophe ;
Hiriart, Jean-Baptiste ;
Okusaka, Takuji ;
Morimoto, Manabu ;
Hsu, Yanzhi ;
Abada, Paolo B. ;
Kudo, Masatoshi .
LANCET ONCOLOGY, 2019, 20 (02) :282-296
234567891011